Disability progression is not always permanent for people with relapsing-remitting multiple sclerosis (RRMS), even when it occurs independent of a relapse, a new study has found. Researchers report that nearly one-third of RRMS patients who experience progression independent of relapse activity (PIRA) see their disability levels ease in the…
RRMS
Autologous hematopoietic stem cell transplant (aHSCT) could slow disease progression in people with relapsing-remitting multiple sclerosis (RRMS), according to a study tracking MS patients in Sweden. The procedure was associated with sustained reductions in biomarkers linked to progressive MS. The results also showed that a significant portion of patients…
The signaling molecule interleukin-6 (IL-6), which is involved in inflammation, is associated with increasing frailty in people with multiple sclerosis (MS), a new study from researchers in China reported. Elevated levels of IL-6 significantly correlated with higher scores on a frailty index that measures health deficits across multiple domains,…
Rituximab, sometimes used off-label as a multiple sclerosis (MS) treatment, may be as effective — at a much lower cost to patients — as the approved therapy Ocrevus (ocrelizumab) at managing relapsing forms of the disease, a new study from Egypt suggests. The study’s results showed that the…
Note: This study was updated March 3, 2025, to correct that a ketogenic diet is a low-carbohydrate, high-fat diet. Eating a version of the low-carbohydrate, high-fat ketogenic diet for six months led to an anti-inflammatory shift in immune cell populations among people with stable, relapsing-remitting multiple sclerosis (RRMS)…
Stem cell transplant can be considered a viable treatment option for people with relapsing-remitting multiple sclerosis (MS) who are young, early in the disease course, do not have other major health issues, and have failed to respond to available medications, according to a new set of recommendations. The procedure…
A large majority of people with relapsing-remitting multiple sclerosis (RRMS) who received Tysabri (natalizumab) in a real-world setting experienced no evidence of disease activity for as long as six years, according to a study from a single center in Hungary. No evidence of disease activity, known as NEDA-3,…
The rate of disability progression among people with relapsing-remitting multiple sclerosis (RRMS) has slowed over the years due to advances in disease-modifying therapies (DMTs), according to a long-term analysis. Patients diagnosed in recent decades have experienced fewer progression events associated with relapses, called relapse-associated worsening (RAW), and also…
SetPoint Medical is planning to launch a clinical trial next year to investigate its nerve stimulator device, intending to support myelin repair, in people with relapsing-remitting multiple sclerosis (RRMS). The announcement comes after U.S. Food and Drug Administration (FDA) approval of an investigational device exemption, allowing the…
A potential treatment of relapsing-remitting multiple sclerosis (RRMS), arsenic trioxide (ATO) has been patented in the European Union based on findings in preclinical studies. Notice of an intent to grant patent EP18722530, titled “Method for treating relapsing-remitting multiple sclerosis using arsenic trioxide,” was given by the European Patent…
People with relapsing-remitting multiple sclerosis (RRMS) who drink low to moderate amounts of alcohol have significantly less disability progression in the years following diagnosis than non-drinkers, a study found. The trend was especially pronounced among women. Although the findings suggest that drinking alcohol may have beneficial effects in some…
The U.S. Food and Drug Administration (FDA) has accepted SetPoint Medical, which is developing a nerve stimulator for people with relapsing-remitting multiple sclerosis (RRMS), into a pilot program designed to promote the development of new medical devices, the company said. The Total Product Life Cycle Advisory Program…
Taking melatonin before bedtime may help balance and muscle strength in people living with multiple sclerosis (MS), according to a study from Tunisia. Those benefits are in addition to making for more restful sleep. While the findings come from a small number of patients, they suggest melatonin supplements may…
The Swank and Wahls diets — two dietary strategies often adopted by people with multiple sclerosis (MS) — were similarly effective at easing functional disability after six months among people with relapsing-remitting MS (RRMS), according to data from a small clinical trial. These functional gains were mostly driven…
People with a higher genetic risk for multiple sclerosis (MS) were seen to have detectable differences in their gut bacteria in a small study. “There seems to be an association between genetic risk score and [changes in gut bacteria] in triggering the disease in a small cohort of MS…
A scoring system that accounts for relapses and MRI activity in multiple sclerosis (MS) patients during their first year on an oral disease-modifying therapy (DMT) was found to be predictive of worse short-term outcomes for people with relapsing forms of the neurodegenerative disorder, a study showed. “The occurrence of…
The risk of developing multiple sclerosis (MS) was similar between first- and second-degree family members of people with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). The findings, which were consistent with previous studies suggesting that genetics and environment are relatively equal contributors to disease risk, also…
Relapsing-remitting multiple sclerosis (RRMS) patients with elevated levels of chloride in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, may be at a higher risk of relapse, according to a study from China. Researchers propose that CSF chloride levels equal to or higher than 123.2…
Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagio’s clinical effectiveness will…
Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening two years after receiving stem cell transplant, according to a real-world study in Denmark. Moreover, more than two-thirds (69%) of these RRMS patients achieved a clinical outcome called NEDA-3, or…
Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability for people with highly active relapsing-remitting multiple sclerosis (RRMS), a new analysis suggests. In contrast, findings suggest that the efficacy of stem cell therapy is not significantly different…
New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeutics’ novel oral treatment candidate for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was found to safely reduce brain lesions and prevent disability progression in…
An eight-week intermittent fasting intervention for people with relapsing-remitting multiple sclerosis (RRMS) led to significant improvements in cognition and manual dexterity for these patients, who also tended to have lower fatigue and pain scores at the program’s end, an exploratory study showed.
The wing of the small aircraft dipped below the horizon, revealing a strip of sand in the middle of the Bering Sea. On one side, miles of ocean. On the other, a lagoon. It was 1995, and Melissa Cook, her husband Elgin, and their three small children were beginning an…
Two years of treatment with the approved therapy >Copaxone (glatiramer acetate) was found to slow the loss of cerebral gray matter and whole brain volume — two markers of neurodegeneration — in people with relapsing-remitting multiple sclerosis (RRMS). Notably, individuals on Copaxone…
A dietary supplement called Neuroaspis plp10 significantly lowered relapse rates and slowed disability progression among people with relapsing-remitting multiple sclerosis (RRMS) on interferon beta medications, according to a small clinical trial in Greece. “The results of this study suggest that Neuroaspis plp10 may offer greater benefit to patients with RRMS…
Medications account for the majority of costs related to managing multiple sclerosis (MS) in Italy, and secondary-progressive MS (SPMS) is associated with higher treatment and healthcare costs than those for relapsing-remitting multiple sclerosis (RRMS), a study looking at real-world data reported. “A bigger healthcare resource consumption was retrieved for…
Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to a final analysis of data from the open-label EVOLVE-MS-1 Phase 3 clinical trial. Indirect comparisons of Vumerity-treated patients against those…
Electrical stimulation of the brain through electrodes placed on the scalp may ease some measures of spasticity for people with relapsing-remitting multiple sclerosis (RRMS), according to results from a small clinical trial. Using this novel route of brain stimulation was shown to impact muscle contractions in patients with spasticity…
People with secondary progressive multiple sclerosis (SPMS) have more microscopic damage in normal-appearing brain tissue than do patients with relapsing-remitting multiple sclerosis (RRMS), according to a new imaging study. These patients also have a greater number of chronic active lesions than those with RRMS. “Using advanced diffusion MRI…